🇪🇺EU · EMAApplication withdrawnATC: L01DB01

Doxorubicin Hydrochloride Tillomed(doxorubicin hydrochloride)

Breast Neoplasms;Ovarian Neoplasms;Multiple Myeloma;Sarcoma, Kaposi

Marketing Authorisation Holder: Laboratorios Tillomed Spain S.L.U

INN: doxorubicin

Indication

Treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Doxorubicin Hydrochloride Tillomed — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Doxorubicin Hydrochloride Tillomed Create Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.